NeuroOne Medical Technologies Corporation will hold a virtual investor webinar on Thursday, March 12, 2026 at 11:30 a.m. Eastern Time. The company, which trades on Nasdaq under the symbol NMTC, announced the event as part of its ongoing investor communications strategy. Management plans to provide a corporate update, discuss growth plans, and offer details about platform technologies, applications, and commercialization efforts. A question-and-answer session will follow the presentation.
The importance of this event extends beyond routine investor relations. NeuroOne operates in the critical medical technology sector focused on neurological disorders, conditions that affect millions of patients worldwide and represent a significant healthcare burden. The company's work has direct implications for improving surgical outcomes and reducing healthcare costs. Investors and industry observers will be listening for updates on how NeuroOne's technologies are progressing toward broader clinical adoption.
NeuroOne's platform includes four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These technologies represent a shift toward minimally invasive approaches in neurological surgery. By combining diagnostic and therapeutic functions, these solutions could potentially reduce hospitalizations, lower surgical procedure counts, and improve patient recovery experiences. The company's research and development efforts also include drug delivery and spinal cord stimulation programs, indicating a broader strategic vision for neurological care.
The webinar's timing suggests NeuroOne may be preparing to share significant developments about its commercialization progress or technological advancements. For patients suffering from neurological conditions, advancements in surgical technology can mean shorter recovery times, reduced complications, and improved quality of life. For the healthcare system, more efficient surgical tools can translate to lower costs and better resource utilization. The medical device industry closely watches companies like NeuroOne that are pushing boundaries in specialized neurological applications.
Participants can access the webinar via webcast at https://www.webcaster4.com/Webcast/Page/2916/53635 or by telephone using U.S. dial-in 888-506-0062 or international dial-in 973-528-0011 with participant access code 358063. A replay will be available through Thursday, March 26, 2026, by calling 877-481-4010 within the United States or 919-882-2331 internationally using replay passcode 53635, or via the webcast link. Additional company information is available at https://nmtc1.com. The original announcement can be viewed at https://www.newmediawire.com.
This investor webinar represents more than a routine financial update—it provides insight into technological developments that could reshape how neurological disorders are surgically treated. As healthcare systems worldwide grapple with increasing neurological disease burdens, from epilepsy to chronic pain conditions, companies developing more precise, less invasive surgical solutions play a crucial role in advancing patient care. The information shared during this event could signal progress toward making these advanced technologies more widely available to patients who need them.
